Dr. John Ponugupati, MD

Dr. Ponugupati practices at Thomas Memorial Hospital in South Charleston, West Virginia, part of West Virginia University Health System.

Dr. Ponugupati's NPI, 1124274303, was assigned on August 7, 2008. Dr. Ponugupati holds West Virginia license 26167.

Dr. Ponugupati's primary practice is Thomas Memorial Hospital, at 4605 Maccorkle Avenue SW, South Charleston, WV 25309 in Kanawha County. The practice phone is (304) 766-3600.

Dr. Ponugupati's primary practice is Thomas Memorial Hospital in South Charleston, West Virginia, part of West Virginia University Health System. Dr. Ponugupati is also affiliated with Charleston Area Medical Center General Hospital. The medical group on file is THS Physician Partners, Inc. Dmand AI also links Dr. Ponugupati to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ponugupati practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ponugupati's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ponugupati is licensed in West Virginia.

CMS data shows 1,600 Medicare services from Dr. Ponugupati across 7 procedure codes in 2024, for 422 Medicare patients. Medicare paid $106,864 for them.

CMS counts 422 Medicare patients who saw Dr. Ponugupati in 2024. The largest group is 65 to 74, with 195 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ponugupati's median patient age at 68, with 56% women.

In 2024, Dr. Ponugupati wrote 1,381 Medicare Part D claims for 217 patients. 69% of them were for generic drugs. CMS names the drug for 1,149 of them, across 39 drugs with 11 or more claims each, at $3,652,532 in total drug cost. In 2023, CMS named 1,089 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Ponugupati for performance year 2024, reported through an alternative payment model (APM). Dr. Ponugupati accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ponugupati as offering telehealth.

Dmand AI links 2 papers to Dr. Ponugupati, published from 2012 to 2016. Dr. Ponugupati's most frequent co-authors are Federico Laurel Ampil, MD, Andrei Balandin and Paige E. Bundrick, MD.

CMS Open Payments shows 240 general payments to Dr. Ponugupati from 34 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Bristol-Myers Squibb Company paid the most, $1,322.